You are browsing articles on the topic of Heart Failure Archives - CardioExchange

Avatar of Larry Husten, PHD

Increased Mortality Risk Found With Digoxin (4 May 2015)

News

For more than 200 years physicians have been trying to figure out how and when to use digoxin. Although it has a narrow therapeutic window and potentially dangerous interactions with other drugs, it is endorsed by current guidelines and widely given to patients with heart failure (HF) and atrial fibrillation (AF). However, there have been no…

This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.

Avatar of Larry Husten, PHD

FDA Approves New Heart Failure Drug (16 Apr 2015)

News

The FDA on Wednesday approved ivabradine (Corlanor), Amgen’s new heart failure drug. The drug has been available for several years in Europe, where it is sold by Servier under the brand names of Corlentor and Procoralan. Ivabradine was approved for the reduction of hospitalization from worsening heart failure. It is indicated for use in stable heart-failure patients who are in sinus rhythm, have a…

This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.

Avatar of Jennifer

Exploring Sex Differences in the Use of Mechanical Circulatory Support for Advanced Heart Failure (26 Feb 2015)

Voices

Jennifer Cook, MD

Jennifer L. Cook discusses differences between men and women in the use of ventricular assist devices for advanced heart failure.

Avatar of Behnood Bikdeli, M.D.

Insights About the Use of IV Fluids in Patients Hospitalized for Heart Failure (12 Feb 2015)

Voices

Behnood Bikdeli, M.D. and Larry Allen, MD, MHS

Behnood Bikdeli and Larry Allen discuss a retrospective study of the potential risks of IV fluids for patients hospitalized with heart failure who were treated with loop diuretics.

Avatar of Joseph

To Shock or Not to Shock — That Is the Question (4 Feb 2015)

Voices

Joseph G Akar, MD/PhD and Jehad Al Buraiki, MD

Jehad Al Buraiki and Joseph G. Akar offer differing perspectives, from each side of the Atlantic, on cardiac resynchronization-pacemaker therapy.

Avatar of Larry Husten, PHD

FDA Approves Right Percutaneous Single Access Heart Pump (29 Jan 2015)

News

Abiomed has announced that it received FDA approval for its Impella RP System, the first percutaneous single access heart pump that provides support to the right side of the heart. The approval, under a Humanitarian Device Exemption (HDE), is based on results of the single-arm Recover Right study, in which 30 patients were enrolled. The…

This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.

Avatar of Leora

Low-Quality Discharge Summaries May Have Consequences (15 Jan 2015)

Voices

Leora Horwitz, MD

Leora Horwitz discusses her research group’s study of the association between the quality of discharge summaries and risk for readmission for heart failure.

Avatar of Eiran

Screening Heart-Failure Patients for Cognitive Impairment at Discharge (5 Jan 2015)

Voices

Eiran Gorodeski, MD, MPH

Eiran Gorodeski discusses his research group’s study of cognitive-impairment screening for patients who are hospitalized for heart failure.

Avatar of Larry Husten, PHD

European Review Confirms Increased Risk with Ivabradine (24 Nov 2014)

News

Following a review provoked by troubling findings that emerged from a large clinical trial, the European Medicines Agency (EMA) is making several recommendations intended to lower the risk of heart problems linked to the heart-rate-lowering drug ivabradine. The drug is marketed by Servier in Europe under the brand names of Corlentor and Procoralan and is indicated for…

This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.

Avatar of Larry Husten, PHD

Encouraging Results for Two New Drugs for Hyperkalemia (21 Nov 2014)

News

Two new agents under development may help curb and prevent hyperkalemia, the common and serious side effect of drugs that inhibit the renin-angiotensin-aldosterone system (RAAS), which are the cornerstones of the treatment of chronic kidney disease and heart failure. In a phase 3 study, published online in the New England Journal of Medicine, researchers first randomized…

This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.